220 related articles for article (PubMed ID: 27056562)
1. Designing and optimization of novel human LMTK3 inhibitors against breast cancer - a computational approach.
Anbarasu K; Jayanthi S
J Recept Signal Transduct Res; 2017 Feb; 37(1):51-59. PubMed ID: 27056562
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Virtual Screening of High-Affinity ATP-Competitive Inhibitors Against Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: A Novel Therapeutic Target for Breast Cancer.
Sarma H; Mattaparthi VSK
Interdiscip Sci; 2019 Sep; 11(3):527-541. PubMed ID: 30066129
[TBL] [Abstract][Full Text] [Related]
3. Identification of curcumin derivatives as human LMTK3 inhibitors for breast cancer: a docking, dynamics, and MM/PBSA approach.
Anbarasu K; Jayanthi S
3 Biotech; 2018 May; 8(5):228. PubMed ID: 29719770
[TBL] [Abstract][Full Text] [Related]
4. Structural modeling and molecular dynamics studies on the human LMTK3 domain and the mechanism of ATP binding.
Anbarasu K; Jayanthi S
Mol Biosyst; 2014 May; 10(5):1139-45. PubMed ID: 24619340
[TBL] [Abstract][Full Text] [Related]
5. Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase.
Ortiz MA; Michaels H; Molina B; Toenjes S; Davis J; Marconi GD; Hecht D; Gustafson JL; Piedrafita FJ; Nefzi A
Bioorg Med Chem Lett; 2020 May; 30(9):127108. PubMed ID: 32192797
[TBL] [Abstract][Full Text] [Related]
6. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.
Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M
J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281
[TBL] [Abstract][Full Text] [Related]
7. LMTK3 is implicated in endocrine resistance via multiple signaling pathways.
Stebbing J; Filipovic A; Lit LC; Blighe K; Grothey A; Xu Y; Miki Y; Chow LW; Coombes RC; Sasano H; Shaw JA; Giamas G
Oncogene; 2013 Jul; 32(28):3371-80. PubMed ID: 22869149
[TBL] [Abstract][Full Text] [Related]
8. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
Agarwal S; Dixit A; Kashaw SK
J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
[TBL] [Abstract][Full Text] [Related]
9. Computational prediction for designing novel ketonic derivatives as potential inhibitors for breast cancer: A trade-off between drug likeness and inhibition potency.
Muhammad S; Zahir N; Bibi S; Alshahrani MY; Shafiq-urRehman ; Chaudhry AR; Sarwar F; Tousif MI
Comput Biol Chem; 2024 Apr; 109():108020. PubMed ID: 38286082
[TBL] [Abstract][Full Text] [Related]
10. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.
Giamas G; Filipović A; Jacob J; Messier W; Zhang H; Yang D; Zhang W; Shifa BA; Photiou A; Tralau-Stewart C; Castellano L; Green AR; Coombes RC; Ellis IO; Ali S; Lenz HJ; Stebbing J
Nat Med; 2011 Jun; 17(6):715-9. PubMed ID: 21602804
[TBL] [Abstract][Full Text] [Related]
11. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
12. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
14. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
15. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
16. Chemoinformatics and machine learning techniques to identify novel inhibitors of the lemur tyrosine kinase-3 receptor involved in breast cancer.
Alrumaihi F
Front Mol Biosci; 2024; 11():1366763. PubMed ID: 38638686
[TBL] [Abstract][Full Text] [Related]
17. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations.
Katari SK; Natarajan P; Swargam S; Kanipakam H; Pasala C; Umamaheswari A
J Recept Signal Transduct Res; 2016 Dec; 36(6):558-571. PubMed ID: 26906522
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening of flavonoids as potential RIPK1 inhibitors for neurodegeneration therapy.
Bepari AK; Shatabda S; Reza HM
PeerJ; 2024; 12():e16762. PubMed ID: 38274328
[TBL] [Abstract][Full Text] [Related]
20. Putative Anti-Cancer Drug Candidate Targeting the 'PLK-1-Polo-Box Domain' by High Throughput Virtual Screening: A Computational Drug Design Study.
Shakil S; Abuzinadah MF
Crit Rev Eukaryot Gene Expr; 2019; 29(3):251-261. PubMed ID: 31679235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
